方盛制药：全资子公司获得《药物临床试验批准通知书》

Group 1 - Company announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for the development of the generic drug RuLuGuoLi tablets [1] - This approval marks a significant step in the company's efforts to expand its pharmaceutical product offerings and enhance its research and development capabilities [1]